From: Synthesis of phthalazine-based derivatives as selective anti-breast cancer agents through EGFR-mediated apoptosis: in vitro and in silico studies
Compound
EGFR
% of inhibition at [10 µM]
IC50 [nM] ± SD*
11d
92.9 ± 2.08
79.6 ± 1.35
12c
96.2 ± 2.04
65.4 ± 1.12
12d
97.6 ± 2.49
21.4 ± 0.67
Erlotinib
93.9 ± 2.68
80.1 ± 1.21